{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:54:18Z","timestamp":1791003258313,"version":"4.1.0"},"reference-count":37,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2026,9,30]]},"DOI":"10.7883\/yoken.jjid.2026.065","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:16:06Z","timestamp":1790720166000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Dynamics of Neutralizing Antibodies after mRNA COVID-19 Vaccination in Psychiatric Inpatients Following an Outbreak"],"prefix":"10.7883","author":[{"given":"Shinji","family":"Nakase","sequence":"first","affiliation":[{"name":"Suzuka Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kusuhara","sequence":"additional","affiliation":[{"name":"Mie Prefecture Health and Environment Research Institute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kanehara","sequence":"additional","affiliation":[{"name":"Suzuka Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Hirano","sequence":"additional","affiliation":[{"name":"Suzuka Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Medical Health, Mie Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Uno","sequence":"additional","affiliation":[{"name":"Department of Medical Health, Mie Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyosu","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"NHO Mie National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Komase","sequence":"additional","affiliation":[{"name":"Japan Institute for Health Security, National Institute of Infectious Diseases, Department of Infectious Disease Surveillance, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Public Health, Occupational Medicine, and Applied Epidemiology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19; 11 March 2020. Available at < https:\/\/www.who.int\/news-room\/speeches\/item\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>. Accessed February 11, 2026."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bojdani E, Rajagopalan A, Chen A, et al. COVID-19 pandemic: impact on psychiatric care in the United States. Psychiatry Res. 2020;289:113069.","DOI":"10.1016\/j.psychres.2020.113069"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kato H, Seki K, Maeda Y, et al. Rapid response to a coronavirus disease 2019 (COVID-19) outbreak in a psychiatry hospital-Kanazawa City, Japan, March to April 2020. Antimicrob Steward Healthc Epidemiol. 2022;2:1-3.e57.","DOI":"10.1017\/ash.2021.255"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tazaki M. Impact of COVID-19 on people with mental disabilities in Japan. J Psychosoc Rehabil Ment Health. 2020;7:113-114.","DOI":"10.1007\/s40737-020-00173-w"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ji H, Liu L, Huang T, et al. Nosocomial infections in psychiatric hospitals during the COVID-19 outbreak. Eur J Psychiatry. 2020;34:177\u2013179.","DOI":"10.1016\/j.ejpsy.2020.04.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chun JY, Jun JY, Choi J, et al. Coronavirus disease 2019 outbreak in a psychiatric closed ward: what we have to learn. Front. Psychiatry. 2021;11:579235.","DOI":"10.3389\/fpsyt.2020.579235"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fond G, Nemani K, Etchecopar-Etchart D, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries. JAMA Psychiatry. 2021;78:1208\u20131217.","DOI":"10.1001\/jamapsychiatry.2021.2274"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Teixeira AL, Krause TM, Ghosh L, et al. Analysis of COVID-19 infection and mortality among patients with psychiatric disorders, 2020. JAMA Netw Open. 2021;4:e2134969.","DOI":"10.1001\/jamanetworkopen.2021.34969"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Vai B, Mazza MG, Delli Colli C, et al. Mental disorders and risk of COVID-19-related mortality, hospitalization, and intensive care unit admission: a systemic review and meta-analysis. Lancet Psychiatry. 2021;8:797\u2013812.","DOI":"10.1016\/S2215-0366(21)00232-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mazereel V, Van Assche K, Detraux J, et al. COVID-19 vaccination for people with severe mental illness: why, what, and how? Lancet Psychiatry. 2021;8:444\u2013450.","DOI":"10.1016\/S2215-0366(20)30564-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tokuda Y, Barnett PB, Sanji S, et al. Serious mental illness and in-hospital mortality among hospitalized patients with acute COVID-19: a large-database analysis in Japan. Gen Hosp Psychiatry. 2023;82:1\u20136.","DOI":"10.1016\/j.genhosppsych.2023.01.014"},{"key":"12","unstructured":"12. Ministry of Health, Labour and Welfare. Diagnostic Guide of COVID-19 9th edition. Available at <https:\/\/www.mhlw.go.jp\/content\/000936655.pdf>. Accessed February 11, 2026. Japanese."},{"key":"13","unstructured":"13. National Institute of Infectious Diseases, COVID-19 Serological Testing Manual ver.1. Available at <https:\/\/id-info.jihs.go.jp\/infectious-diseases\/covid-19\/COVID-19Serology_Ver1.pdf>. Accessed February 11, 2026. Japanese."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69:440\u2013447.","DOI":"10.1111\/pcn.12275"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Warren N, Kisely S, Siskind D. Maximizing the uptake of a COVID-19 vaccine in people with severe mental illness. JAMA Psychiatry. 2021;78:589\u2013590.","DOI":"10.1001\/jamapsychiatry.2020.4396"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Siva N. Severe mental illness: reassessing COVID-19 vaccine priorities. Lancet. 2021;397:657.","DOI":"10.1016\/S0140-6736(21)00429-3"},{"key":"17","unstructured":"17. Ministry of Health, Labour and Welfare. Notice on COVID-19 vaccination. Available at <https:\/\/h-crisis.niph.go.jp\/wp-content\/uploads\/2021\/09\/20210906105707_content_000759274.pdf>. Accessed February 11, 2026."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bitan DT, Kridin K, Cohen AD, et al. COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study. Lancet Psychiatry. 2021;8:901\u2013908.","DOI":"10.1016\/S2215-0366(21)00256-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Trinite B, Tarr\u00e9s-Freixas F, Rodon J, et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci Rep. 2021;11:2608.","DOI":"10.1038\/s41598-021-81862-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Legros V, Denolly S, Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18:318\u2013327.","DOI":"10.1038\/s41423-020-00588-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476\u2013488.","DOI":"10.1016\/j.cell.2020.12.015"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. M\u00fcller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018;44:973\u2013982.","DOI":"10.1093\/schbul\/sby024"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tamouza R, Krishnamoorthy R, Leboyer M. Understanding the genetic contribution of the human leukocyte antigen system to common major psychiatric disorders in a world pandemic context. Brain Behav Immun. 2021;91:731\u2013739.","DOI":"10.1016\/j.bbi.2020.09.033"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. May M, Slitzky M, Rostama B, et al. Antipsychotic-induced immune dysfunction: a consideration for COVID-19 risk. Brain Behav Immun Health. 2020;6:100097.","DOI":"10.1016\/j.bbih.2020.100097"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pradenas E, Trinit\u00e9 B, Urrea V, et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Medicine. 2021;2:313\u2013320.e4.","DOI":"10.1016\/j.medj.2021.01.005"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227\u20131230.","DOI":"10.1126\/science.abd7728"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Vicenti I, Gatti F, Scaggiante R, et al. Time course of neutralizing antibody in health care workers with mild or asymptomatic COVID-19 infection. Open Forum Infect Dis. 2021;8:ofab312.","DOI":"10.1093\/ofid\/ofab312"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368:945\u2013946.","DOI":"10.1126\/science.abb8923"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Polack FP, Thomas SJ, Kitchin N, et al. Efficacy and safety of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603\u20132615.","DOI":"10.1056\/NEJMoa2034577"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u2013416.","DOI":"10.1056\/NEJMoa2035389"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Vicenti I, Gatti F, Scaggiante R, et al. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. Int J Infect Dis. 2021;108:176\u2013178.","DOI":"10.1016\/j.ijid.2021.05.033"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Demonbreun AR, Sancilio A, Velez MP, et al. Comparison of IgG and neutralizing antibody response after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine. 2021;38:101018.","DOI":"10.1016\/j.eclinm.2021.101018"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Manisty C, Otter AD, Treibel TA, et al. Antibody response to the first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397:1057\u20131058.","DOI":"10.1016\/S0140-6736(21)00501-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Saadat S, Rikhtegaran Tehrani Z, Logue J, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021;325:1467\u20131468.","DOI":"10.1001\/jama.2021.3341"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Farvesse J, Gillot C, Di Chiaro L, et al. Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2. Viruses. 2021;13:1364.","DOI":"10.3390\/v13071364"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Shirato K, Nao N, Katano H, et al. Development of genetic diagnostic methods for detection of novel coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis. 2020;73:304\u2013307.","DOI":"10.7883\/yoken.JJID.2020.061"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Nagura-Ikeda M, Imai K, Kubota K, et al. Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan. J Med Microbiol. 2021;70:001291.","DOI":"10.1099\/jmm.0.001291"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2026.065\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:34:25Z","timestamp":1791002065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2026.065\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2026.065","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"JJID.2026.065"}}